Proliferative Vitreoretinopathy (PVR) Drug Pipeline Guide 2021

DUBLIN, Sept. 24, 2021 /PRNewswire/ -- The "Proliferative Vitreoretinopathy (PVR) (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.

The latest pipeline guide provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Proliferative Vitreoretinopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Proliferative Vitreoretinopathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Proliferative Vitreoretinopathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Proliferative Vitreoretinopathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Proliferative Vitreoretinopathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (Ophthalmology)

Key benefits:

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Proliferative Vitreoretinopathy (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Proliferative Vitreoretinopathy (PVR) - Overview
• Pipeline Overview
• Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment
• Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development
• Proliferative Vitreoretinopathy (PVR) - Drug Profiles
• Proliferative Vitreoretinopathy (PVR) - Dormant Projects
• Proliferative Vitreoretinopathy (PVR) - Product Development Milestones
• Featured News & Press Releases

Companies Mentioned

• Aldeyra Therapeutics Inc
• Aptitude Medical Systems Inc
• Focal Point Pharmaceuticals Inc
• Novartis AG
• Panag Pharma Inc

For more information about this report visit https://www.researchandmarkets.com/r/epuqb1

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets